Athira Pharma, Inc. - Common Stock (ATHA)
Frequently Asked Questions About Athira Pharma, Inc. - Common Stock (ATHA)
How can investors get involved with Athira Pharma?
Investors interested in Athira Pharma can participate by purchasing shares on the Nasdaq under the ticker symbol 'ATHA'. Additionally, they can stay informed about the company's latest developments, clinical trial results, and strategic initiatives through press releases, financial reports, and investor presentations available on the company's website.
How does Athira Pharma address the challenges of neurodegenerative diseases?
Athira Pharma addresses the challenges of neurodegenerative diseases by targeting fundamental biological pathways involved in neuronal repair and regeneration. By focusing on these underlying mechanisms, Athira aims to develop treatments that can potentially halt or reverse the progression of diseases like Alzheimer's.
How does Athira Pharma define its competitive advantage?
Athira Pharma defines its competitive advantage through its unique scientific approach to treating neurodegenerative diseases, driven by a robust pipeline of proprietary drug candidates. The company leverages its cutting-edge research and strong intellectual property portfolio to differentiate itself in a highly competitive marketplace.
How does Athira Pharma ensure patient safety in clinical trials?
Athira Pharma prioritizes patient safety in its clinical trials by adhering to rigorous regulatory standards and protocols set forth by agencies such as the FDA. The company conducts thorough preclinical studies and closely monitors all participants throughout the trial process to quickly identify any adverse reactions and ensure participant well-being.
How is Athira Pharma funded?
Athira Pharma has been funded through a combination of private investments, public offerings, and collaborations with other biotech and pharmaceutical firms. The company went public in 2020, raising capital to support its clinical development programs and expansion efforts.
What are the primary therapeutic areas Athira focuses on?
Athira Pharma primarily focuses on neurodegenerative diseases, with a specific emphasis on Alzheimer's disease and related disorders. The company aims to address the significant unmet medical needs in these areas through innovative treatments that target the underlying mechanisms of these conditions.
What does Athira Pharma, Inc. do?
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for neurodegenerative diseases, particularly Alzheimer's and Parkinson's diseases. The company aims to restore neuronal health and improve cognitive function through its innovative drug candidates, primarily targeting the underlying biology of these diseases.
What impact has the COVID-19 pandemic had on Athira?
The COVID-19 pandemic impacted many biotech firms, including Athira Pharma, by introducing delays in clinical trials and research timelines. However, the company adapted by implementing safety protocols and leveraging digital solutions to continue its operations and maintain momentum in drug development.
What is Athira Pharma's market strategy?
Athira Pharma's market strategy focuses on establishing itself as a leader in the neurotherapeutics space by leveraging its innovative drug pipeline, scientific expertise, and strategic partnerships. The company aims to build a strong presence in the biopharmaceutical industry while addressing critical unmet needs in patient populations affected by neurodegenerative diseases.
What is the company's approach to drug development?
Athira Pharma employs a science-driven approach to drug development, focusing on discovering and developing small molecules that can enhance neuronal health and function. This is achieved through rigorous preclinical studies and clinical trials designed to generate strong evidence of safety and efficacy for their therapeutics.
What is the company's vision for the future?
Athira Pharma's vision for the future is to become a leading provider of innovative therapies that deliver meaningful improvements in cognitive function and quality of life for patients suffering from neurodegenerative diseases. The company aims to transform how these conditions are treated and managed through breakthrough scientific advancements.
What is the outlook for Athira Pharma's stock?
The outlook for Athira Pharma's stock is influenced by several factors, including the progress of its clinical trials, regulatory developments, and overall market conditions in the biotech sector. Investors often closely monitor the company's announcements regarding trial results and partnerships, as these can significantly impact stock performance.
What is the significance of ATH-1017?
ATH-1017 is Athira Pharma's lead drug candidate, designed to be used in the treatment of Alzheimer's disease. It is a small molecule that aims to promote neuronal growth and repair by targeting key pathways involved in neurodegeneration, and it is currently undergoing clinical trials to assess its safety and efficacy.
What partnerships or collaborations does Athira Pharma have?
Athira Pharma has established partnerships with various academic institutions and biotech companies to advance its research and development initiatives. These collaborations help leverage external expertise and resources, particularly in areas related to Alzheimer's disease and other neurodegenerative conditions.
What role does innovation play in Athira Pharma's research?
Innovation plays a critical role in Athira Pharma's research by fostering the development of novel therapeutics that can fundamentally change the treatment landscape for neurodegenerative diseases. The company's commitment to scientific discovery and technological advancement enables it to explore new strategies for drug development and optimize patient outcomes.
What stage of development are Athira's drug candidates in?
As of October 2023, Athira's drug candidates, particularly ATH-1017, are in various stages of clinical trials. The company is progressing through Phases 1 and 2 trials to evaluate the safety, tolerability, and efficacy of their treatments in patients with neurodegenerative diseases.
When was Athira Pharma founded?
Athira Pharma was founded in 2013 by Dr. Leen Kawas, a dedicated scientist in the field of neurology and pharmaceuticals. The company emerged from the University of Washington's research programs and has since grown to establish itself as a leader in developing novel treatments for neurodegenerative conditions.
Where is Athira Pharma headquartered?
Athira Pharma is headquartered in Seattle, Washington. This location is strategic for the company as it is situated in a hub of biotechnology and life sciences, allowing access to a rich ecosystem of research institutions and potential partnerships.
Who are the key members of Athira Pharma's leadership team?
Athira Pharma's leadership team includes CEO Dr. Leen Kawas, who has a strong background in neuroscience and drug development, along with a team of experienced professionals in various fields such as clinical research, regulatory affairs, and corporate strategy who drive the company's vision and operational execution.
What is the current price of Athira Pharma, Inc. - Common Stock?
The current price of Athira Pharma, Inc. - Common Stock is 0.2500
When was Athira Pharma, Inc. - Common Stock last traded?
The last trade of Athira Pharma, Inc. - Common Stock was at 2:54 pm EDT on April 4th, 2025
What is the market capitalization of Athira Pharma, Inc. - Common Stock?
The market capitalization of Athira Pharma, Inc. - Common Stock is 9.51M
How many shares of Athira Pharma, Inc. - Common Stock are outstanding?
Athira Pharma, Inc. - Common Stock has 38.05M shares outstanding.